Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Overview | Financials
Company Name | Enanta Pharmaceuticals, Inc. |
Symbol | ENTA |
Currency | USD |
Price | 6.1 |
Market Cap | 129,285,230 |
Dividend Yield | 0% |
52-week-range | 5.7 - 17.8 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jay R. Luly Ph.D. |
Website | https://www.enanta.com |
An error occurred while fetching data.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD